ZM-241385

Research use only, not for human use.

ZM-241385 is a potent, non-xanthine A2A selective adenosine receptor antagonist with rat PC12 binding pIC50 of 9.52.

ZM-241385 is a potent, non-xanthine A2A selective adenosine receptor antagonist with rat PC12 binding pIC50 of 9.52; shows low affinity for A3 (pIC50=3.82); antagonizes vasodilatation of the coronary bed produced by 2-CADO and CGS21680 with pA2 of 8.57 and 9.02, respectively, in guinea-pig isolated Langendorff hearts; selectively attenuates the mean arterial blood pressure response produced by exogenous adenosine in conscious spontaneously hypertensive rats (3-10 mg/kg, p.o.).

ZM241385 (1 μM; 24-48 hours; PC12 cells) treatment reverses the phenomenon that A2AR agonist CGS21680 significantly upregulates A2AR mRNA and protein levels. RT-PCR Cell Line:PC12 cells Concentration:1 μM Incubation Time:24 hours Result:Suppressed the increased A2AR mRNA levels engendered by CGS21680.Western Blot Analysis Cell Line:PC12 cells Concentration:1 μM Incubation Time:48 hours Result:Decreased A2AR protein levels

ZM241385 (0.2 μg/mouse, 0.4 μg/mouse; intraperitoneal injection; every day; for 11 weeks; female C57BL/6 WT mice) treatment decreases tumor volume, activates CD8+ T cells and reduces the frequency of splenic MDSC. Animal Model:Female C57BL/6 WT mice received 4-nitroquinoline-N-oxide Dosage:0.2 μg/mouse, 0.4 μg/mouse Administration:Intraperitoneal injection; every day; for 11 weeks Result:Decreased tumor volume, activates CD8+ T cells and reduces the frequency of splenic MDSC.

ZM-241385 | ZM 241385

Apoptosis

Adenosine Receptor

A2A

Neurological Disease

——

139180-30-6

337.336

C16H15N7O2

>98% (HPLC)

DMSO: ≥ 30 mg/mL

OC1=CC=C(CCNC2=NC3=NC(C4=CC=CO4)=NN3C(N)=N2)C=C1

Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-

(-20℃)

With Ice Pack

≥ 2 years